KNOWLEDGE is POWER / REAL NEWS is KEY
New York: Wednesday, April 02, 2025
© 2025 U-S-NEWS.COM
Online Readers: 326 (random number)
New York: Wednesday, April 02, 2025
Online: 337 (random number)
Join our "Free Speech Social Platform ONGO247.COM" Click Here
Politics: dr. mccullough weighs in: the history & future of

POLITICS: Dr. McCullough Weighs In: The History & Future of GLP-1s

🔴 Website 👉 https://u-s-news.com/
Telegram 👉 https://t.me/usnewscom_channel


(Note: Thank you for supporting businesses like the one presenting a sponsored message below and working with them through the links below which benefits Pro Trump News. We appreciate your support!)



In a recent article by Dr. Peter McCullough, he explores the evolution of GLP-1 receptor agonists and their expanding role beyond diabetes treatment.

The journey began in 2005 with the FDA approval of exenatide (Byetta), setting the stage for a new class of medications that regulate blood sugar and appetite.

A Timeline of GLP-1 Advancements:

2005 – Exenatide (Byetta) approved for type 2 diabetes

2010 – Liraglutide (Victoza) enters the market

2017 – Semaglutide (Ozempic & oral Rybelsus) gains approval

2022 – Tirzepatide (Mounjaro) emerges as a dual-receptor agonist

These drugs influence key metabolic pathways, offering benefits for both diabetes and weight loss. However, they come with limitations—most require injections, clinical oversight, and ongoing prescriptions.

The Next Step: Retatrutide & The Power of Triple-Receptor Agonism

As Dr. McCullough discusses, retatrutide (LY3437943) represents the next evolution in GLP-1 therapies, targeting three key receptors:

– GLP-1 for appetite control & glucose regulation

– GIP to enhance insulin sensitivity

– Glucagon to promote fat metabolism

While injectable retatrutide is still under clinical investigation, early data suggests it is more effective than its predecessors. However, many individuals want a more flexible, private, and patient-controlled solution for weight loss.

Introducing DROP: A Revolutionary Approach to Weight Management

The Wellness Company developed DROP — an oral retatrutide formula — designed to support metabolic health without the barriers of traditional GLP-1 therapies.

Encapsulated in liposomes for enhanced absorption, DROP provides an alternative solution for those seeking appetite control and weight management in a non-injectable form.

If you’ve considered GLP-1 treatments but want a more discreet, adaptable option, click here to see if DROP may be the solution you’ve been looking for.

Start Today and Get $100 Off* Your First Month

For a limited time, new customers get $100 off* their first DROP subscription when they enter the code PTN100 at checkout.

Your healthier alternative is here.

No needles. No restrictive diets. Just a smarter approach to weight management.

Click here to see if DROP is right for you.

Note: The information provided on this website is intended for informational purposes only and should not be considered medical advice or used as a substitute for professional healthcare guidance. It is your responsibility to comply with all applicable laws, regulations, and guidelines regarding the purchase, possession, and use of prescription medications.

* Discount will be automatically applied to your purchase when promo code is entered at checkout. Offer valid for new customers only. Discount of $100 applies to the first month of subscription. Cannot be combined with other offers or promotions. Terms and conditions apply. While supplies last.





Source link



OnGo247
New 100% Free
Social Platform
ONGO247.COM
Give it a spin!
Sign Up Today
OnGo247
New 100% Free
Social Platform
ONGO247.COM
Give it a spin!
Sign Up Today